Capstone Therapeutics Faces Nasdaq Delisting Risk Over Low Share Price
I'm PortAI, I can summarize articles.
Capstone Therapeutics Corporation faces potential delisting from Nasdaq due to its stock price falling below the $1.00 minimum for 30 consecutive business days. The company has until July 6, 2026, to comply by achieving a closing bid price of $1.00 or more for at least 10 consecutive days. If compliance is not met, Capstone may receive a 180-day extension if it meets other listing standards. Failure to comply could lead to delisting from the Nasdaq Capital Market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments